Serum Interleukin-33 in Rheumatoid Arthritis and its Relation to Disease Activity | ||
| Suez Canal University Medical Journal | ||
| Article 11, Volume 21, Issue 2, October 2018, Pages 132-139 PDF (258.55 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/scumj.2018.43593 | ||
| Authors | ||
| Mai S. Shalaby1; Mona I. Salama2; Rasha E. Badr* 3; Amany M. Hassan1; Amal S. Ahmed4; Aziza S. Omar5 | ||
| 1Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Egypt | ||
| 2Department of Clinical Pathology, Faculty of Medicine, Port Said University, Egypt | ||
| 3Department of Clinical Pathology, Faculty of Medicine, Port Said University Egypt, | ||
| 4Department of Clinical Pathology, Faculty of Medicine, Suez Canal University | ||
| 5Department of Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Egypt | ||
| Abstract | ||
| Background: Rheumatoid Arthritis (RA) is a chronic progressive, systemic inflammatory, connective tissue disease affecting approximately 1% of the general population. Interleukin-33 (IL33), a member of the IL-1 family, is a ligand for the orphan receptor ST2 (known as IL-1RL1 also). IL-33 is crucial for Th2 cytokine-mediated immune responses however; it can overcome this role in RA. Aim: This study aimed to investigate the potential role of inflammatory cytokine (IL-33) in RA and assess the correlation of IL-33 level to disease activity. Subjects and Method: The study included sixty patients with RA. Patients were diagnosed according to the American College of Rheumatology (ACR) 2010 revised criteria and were classified into 2 groups of 30 patients each according to disease activity score 28 (DAS28), the first group included RA patients with DAS28 of ≤2.4 and the second group included RA patients with DAS28 >2.4.Thirty normal subjects served as a control group. Serum IL-33 was measured using ELISA. Results: Serum IL33 level was significantly higher in patient's group compared to the control group (P ≤.001). Also, serum IL33 level, was significantly higher in patients’ group 2 (DAS>2.4) than patients’ group 1 (DAS≤2.4) (P<0.001). Serum IL-33 level positively correlated with disease duration, ESR, CRP and disease severity. Conclusion: IL-33 is a novel potential marker for the risk of RA as well as a marker of disease activity | ||
| Keywords | ||
| Rheumatoid Arthritis; cytokine; IL-33; disease activity | ||
|
Statistics Article View: 319 PDF Download: 793 |
||
